← All Dbv Technologies SA filings

Dbv Technologies SA 8-K filings

NASDAQ
DBVT
Dbv Technologies SA
8-K: DBV Technologies Announces 1-for-2 Reverse ADS Split to Regain Nasdaq Compliance
DBV Technologies plans a reverse split of its American Depositary Shares (ADS) to increase the share price and meet Nasdaq's minimum bid price requirement.
NASDAQ
DBVT
Dbv Technologies SA
8-K: DBV Technologies Amends Bylaws and Holds Annual General Meeting, Approving Key Resolutions
DBV Technologies amended its bylaws to reflect a change in registered office and held its Annual General Meeting, where shareholders voted on various proposals including financial statements, director appointments, and capital raising authorizations.
NASDAQ
DBVT
Dbv Technologies SA
8-K: DBV Technologies Reports Q1 2024 Financial Results and Business Update
DBV Technologies announced its first quarter 2024 financial results, highlighting progress in its VITESSE clinical trial and the appointment of a new Chief Regulatory Officer.
NASDAQ
DBVT
Dbv Technologies SA
8-K: DBV Technologies Files 2023 Annual Report and Universal Registration Document
DBV Technologies has announced the filing of its 2023 Annual Report on Form 10-K with the SEC and its Universal Registration Document with the French market authority.
NASDAQ
DBVT
Dbv Technologies SA
8-K: DBV Technologies Reports Full Year 2023 Results and Provides Business Update
DBV Technologies announced its full year 2023 financial results and provided a business update, highlighting progress in its Viaskin Peanut clinical development programs and a strengthened leadership team.